← Leaderboards
K Michael Gibson
Oregon Health And Science University
$9,768,649
Attributed
$10,029,847
Total exposure
11
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2006–21$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$10,029,847 · 11
By mechanism
R01$8,924,916 · 5
R41$448,031 · 2
R21$432,400 · 1
R03$143,500 · 1
R13$81,000 · 2
Top collaborators
- Alice Mcconnell2 shared
- Jean-Baptiste O Roullet1 shared
Most similar at Oregon Health And Science University
Same institution · by research overlap
- Jean-Baptiste O Roullet$2,102,469
Others in their field
Top investigators on “Succinate-Semialdehyde Dehydrogenase Deficiency”
- Phillip Lawrence Pearl · Boston Children'S Hospital$1,438,626
- Alexander Rotenberg · Boston Children'S Hospital$970,665
- Jean-Baptiste O Roullet · Oregon Health And Science University$696,857
- Hing Cheong Henry Lee · Boston Children'S Hospital$483,915
- Alice McConnell · Speragen, Inc.$409,871
- Mustafa None Sahin · Children'S Hospital Boston$233,915
Research focus
Succinate-Semialdehyde Dehydrogenase DeficiencyGamma-Aminobutyric AcidPhenotypeEvaluationMetabolismNeurotransmittersFunctional DisorderDesignReceptorAldehyde DehydrogenasesBrainNeurologicPre-ClinicalAnimalsAdultDefectCerebrospinal FluidSiteSuccinate-Semialdehyde DehydrogenaseMediatingMetabolic DiseasesResearch PersonnelElectroencephalographySeizures
Grant awards (40)
Natural History of Succinic Semialdehyde Dehydrogenase Deficiency (SSADHD), a Heritable Disorder of GABA Metabolism$611,058
R01 · FY2021 · HD · contact PI
Natural History of Succinic Semialdehyde Dehydrogenase Deficiency (SSADHD), a Heritable Disorder of GABA Metabolism$633,886
R01 · FY2020 · HD · contact PI
Rapalog Therapy in Heritable and Vigabatrin-Induced GABA Metabolic Disorders$395,549
R01 · FY2020 · EY · contact PI
Natural History of Succinic Semialdehyde Dehydrogenase Deficiency (SSADHD), a Heritable Disorder of GABA Metabolism$640,535
R01 · FY2019 · HD · contact PI
Rapalog Therapy in Heritable and Vigabatrin-Induced GABA Metabolic Disorders$395,549
R01 · FY2019 · EY · contact PI
Natural History of Succinic Semialdehyde Dehydrogenase Deficiency (SSADHD), a Heritable Disorder of GABA Metabolism$686,980
R01 · FY2018 · HD · contact PI
Rapalog Therapy in Heritable and Vigabatrin-Induced GABA Metabolic Disorders$469,376
R01 · FY2018 · EY · contact PI
Farnesol as Novel Treatment in Succinic Semialdehyde Dehydrogenase Deficiency (SSADHD)$223,095
R41 · FY2018 · NS
Rapalog Therapy in Heritable and Vigabatrin-Induced GABA Metabolic Disorders$395,119
R01 · FY2017 · EY · contact PI
Rapalog Therapy in Heritable and Vigabatrin-Induced GABA Metabolic Disorders$86,459
R01 · FY2017 · EY · contact PI
Preclinical Evaluation of NCS-382 in Succinic Semialdehyde Dehydrogenase Deficiency (SSADHD)$224,936
R41 · FY2016 · NS
Phase II Trial of SGS-742 in Succinic Semialdehyde Dehydrogenase Deficiency$209,643
R01 · FY2016 · NS · contact PI
Placebo-Controlled Phase II Trial of SGS742 (GABAB receptor antagonist) in Succinic Semialdehyde Dehydrogenase (SSADH) Deficiency, a Disorder$134,937
R01 · FY2016 · NS · contact PI
Therapeutics of mTOR Signaling in Succinic Semialdehyde Dehydrogenase Deficiency$222,629
R21 · FY2015 · NS · contact PI
Phase II Trial of SGS-742 in Succinic Semialdehyde Dehydrogenase Deficiency$174,168
R01 · FY2015 · NS · contact PI
Therapeutics of mTOR Signaling in Succinic Semialdehyde Dehydrogenase Deficiency$209,771
R21 · FY2014 · NS · contact PI
Phase II Trial of SGS-742 in Succinic Semialdehyde Dehydrogenase Deficiency$172,339
R01 · FY2014 · NS · contact PI
Novel Treatment & Screening Strategies in Gamma-Hydroxybutyric Aciduria$259,430
R01 · FY2013 · HD · contact PI
Phase II Trial of SGS-742 in Succinic Semialdehyde Dehydrogenase Deficiency$186,083
R01 · FY2013 · NS · contact PI
Novel Treatment & Screening Strategies in Gamma-Hydroxybutyric Aciduria$270,091
R01 · FY2012 · HD · contact PI
Novel Treatment & Screening Strategies in Gamma-Hydroxybutyric Aciduria$269,926
R01 · FY2011 · HD · contact PI
Novel Treatment & Screening Strategies in Gamma-Hydroxybutyric Aciduria$356,009
R01 · FY2010 · HD · contact PI
Novel Treatment & Screening Strategies in Gamma-Hydroxybutyric Aciduria$264,992
R01 · FY2009 · HD · contact PI
Murine Knockout Model of 4-Hydroxybutyric Aciduria$181,644
R01 · FY2009 · NS · contact PI
Murine Knockout Model of 4-Hydroxybutyric Aciduria$86,356
R01 · FY2009 · NS · contact PI
Murine Knockout Model of Mevalonic Aciduria$48,194
R03 · FY2009 · HD · contact PI
Novel Treatment & Screening Strategies in Gamma-Hydroxybutyric Aciduria$40,327
R01 · FY2009 · HD · contact PI
Novel Treatment & Screening Strategies in Gamma-Hydroxybutyric Aciduria$38,366
R01 · FY2009 · HD · contact PI
Murine Knockout Model of Mevalonic Aciduria$23,556
R03 · FY2009 · HD · contact PI
Murine Knockout Model of 4-Hydroxybutyric Aciduria$274,733
R01 · FY2008 · NS · contact PI
Murine Knockout Model of Mevalonic Aciduria$71,750
R03 · FY2008 · HD · contact PI
Murine Knockout Model of 4-Hydroxybutyric Aciduria$274,733
R01 · FY2007 · NS · contact PI
Medical Management of Pediatric Neurotransmitter Disorders- A Multidisciplinary$33,000
R13 · FY2007 · NS · contact PI
Murine Knockout Model of 4-Hydroxybutyric Aciduria$282,938
R01 · FY2006 · NS · contact PI
MURINE KNOCKOUT MODEL OF 4-HYDROXYBUTYRIC ACIDURIA$275,235
R01 · FY2003 · NS
MURINE KNOCKOUT MODEL OF 4-HYDROXYBUTYRIC ACIDURIA$275,235
R01 · FY2002 · NS
Symposium on Pediatric Neurotransmitter Disease$48,000
R13 · FY2002 · NS
MURINE KNOCKOUT MODEL OF 4-HYDROXYBUTYRIC ACIDURIA$20,000
R01 · FY2002 · NS
MURINE KNOCKOUT MODEL OF 4-HYDROXYBUTYRIC ACIDURIA$275,235
R01 · FY2001 · NS
MURINE KNOCKOUT MODEL OF 4-HYDROXYBUTYRIC ACIDURIA$287,985
R01 · FY2000 · NS